Careers  |  Sign In  |  Register  |   Twitter

Envarsus: Advancing Kidney Transplantation Through Improved Patient Compliance

John Weinberg, MD, COO, Veloxis Pharmaceuticals, talks about the challenges in current organ transplantation methods, and Veloxis’ once-daily solution to advancing kidney transplantation. According to Weinberg, most kidney transplants fail in the long run, lasting only 10-12 years, a likely result of poor patient compliance with medication. Other challenges include toxicities such as tremor, insomnia, diabetes, hypertension, and renal failure.

Veloxis’ Envarsus is a reformulation of tacrolimus that possesses numerous benefits to help improve patient compliance including:

1. Improved Bioavailability

2. Once-Daily Dosing

3. Lower Peak Concentration

Resources & References

http://www.veloxis.com/envarsus.cfm

http://www.veloxis.com/about_management.cfm